MYB

Overview

MYB (v-myb avian myeloblastosis viral oncogene homolog) is a transcription factor controlling cell survival and proliferation. In IDH-mutant gliomas, MYB is upregulated following treatment-associated DNA hypomethylation, contributing to the epigenetic evolution of glioma under therapy.

Alterations observed in the corpus

  • Upregulated after treatment-associated DNA hypomethylation in IDH-mutant gliomas; controls cell survival and proliferation; observed in the context of glioma progression under temozolomide and/or radiotherapy PMID:38117484.
  • Activation via t(6;9) MYB-NFIB fusion in 57% of ACC cases; exon 10 splice/coding mutations and 5 homozygous deletions in 8%; disrupts leucine-rich negative regulatory domain, likely conferring constitutive activation PMID:23685749
  • Activation via t(6;9) MYB-NFIB fusion in 19/24 ACC cases; copy-number breakpoints at MYB locus on SNP6 in many cases PMID:23778141
  • Canonical MYB::NFIB fusion in 49/88 (57%) of sinonasal adenoid cystic carcinomas; noncanonical fusion partners include ACTB, ACTN4, ESRRG, and EWSR1 fusing MYB exons 2–3 in-frame; MYB FISH detected additional fusion-negative rearrangements PMID:24418857
  • Partner of t(6;9) MYB-NFIB fusion in 10/12 (83%) breast adenoid cystic carcinomas (AdCC); recurrently mutated by missense in 2/12 (17%) cases; one mutation in exon 13 splice site of MYB-NFIB fusion allele PMID:26095796
  • t(6;9) MYB-NFIB fusions present in ~53% of 102-tumor ACC cohort; MYB alterations correlate with worse outcome (recurrence/metastasis P=0.042, shorter survival vs MYBL1-altered P=0.010) PMID:26631609
  • Recurrent rearrangement target in ACC (15/20 cases); enhancer hijacking by translocated super-enhancers drives MYB overexpression via a positive feedback loop; MYB binding (13,278 peaks) cooperates with TP63 and NOTCH1 programs PMID:26829750
  • t(6;9) MYB–NFIB fusion in 11/25 ACC tumors; MYB overexpressed vs. normal (p<0.001) and significantly higher in fusion-positive tumors (p<0.001) PMID:26862087

Cancer types (linked)

  • IDH-mutant glioma (astrocytoma, diffuse glioma) — MYB upregulation is a consequence of epigenetic evolution (GCIMP-high to GCIMP-low transition) driven by treatment PMID:38117484.

Co-occurrence and mutual exclusivity

  • Co-upregulated with RSPO4 (Wnt/beta-catenin pathway agonist) following treatment-associated hypomethylation in IDH-mutant gliomas PMID:38117484.

Therapeutic relevance

  • MYB upregulation represents a treatment-induced epigenetic change; whether targeting MYB in recurrent gliomas provides clinical benefit has not been evaluated in this corpus.

Open questions

  • Whether MYB upregulation in recurrent IDH-mutant glioma is a driver of progression or a bystander of epigenetic remodeling requires experimental validation.

Sources

This page was processed by crosslinker on 2026-05-09. - PMID:23685749

This page was processed by crosslinker on 2026-05-09. - PMID:23778141

This page was processed by crosslinker on 2026-05-09. - PMID:24418857

This page was processed by crosslinker on 2026-05-09. - PMID:26095796

This page was processed by wiki-cli on 2026-05-14. - PMID:26631609

This page was processed by wiki-cli on 2026-05-14. - PMID:26829750

This page was processed by wiki-cli on 2026-05-14. - PMID:26862087

This page was processed by wiki-cli on 2026-05-14.